UNSPSC 51141582: Tiagabine

This classification denotes an anticonvulsant agent with the molecular formula C20H25NO2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z80I64HMNP, chemically known as 3-piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-, (r)- but generally known as tiagabine, which bears US NIH Compound Identifier 60648. European Medicines Agency schedules Tiagabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11000MIG.

UNSPSC 51141582 Tiagabine is a Commodity code representing a specific anticonvulsant pharmaceutical product. The recent state and local opportunities tagged under this code do not align with tiagabine procurement — instead, they reflect broader pharmaceutical supply agreements for naloxone, multi-source generics, and direct-to-manufacturer prescription programs. State and local purchasing offices tag pharmaceutical solicitations at the specific drug or product level, but the recent activity here shows that jurisdictions are more commonly aggregating multiple therapeutic categories (anticonvulsants, opioid antagonists, over-the-counter products) into cooperative purchasing vehicles or health-system-wide supply contracts rather than soliciting individual drugs by UNSPSC commodity code. The issuing bodies reflect the full range of state and local health procurement: county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities in Minnesota and Oregon).

The geographic spread is limited to three jurisdictions in recent activity: Florida, Texas, and Minnesota-Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for naloxone and drug deactivation systems with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription models outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers effective July 1, 2026. The code shows minimal relevant recent activity — no dedicated tiagabine procurements appear in the record. If pursuing under this code, focus on multistate cooperative vehicles and health system supply agreements that bundle multiple pharmaceutical categories rather than single-drug commodity solicitations.